Please login to the form below

Not currently logged in
Email:
Password:

GSK sells Italian research unit to Aptuit

GSK is to sell its Medicines Research Centre in Verona, Italy to Aptuit Inc who will continue to employ all 500 staff who work at the centre
GlaxoSmithKline (GSK) has finalised a deal to sell its Medicines Research Centre in Verona, Italy to Aptuit Inc. As part of the agreement, around 500 staff currently employed at the centre by GSK will be kept on by Aptuit – providing the company with their scientific knowledge and expertise.

Aptuit will supply GSK with R&D services from the facilities. The acquisition will allow Aptuit to provide integrated development services to its global customers while keeping the existing pool of life science research experts in Italy.

The financial terms of the deal have not been disclosed.

Tim Tyson, chairman and CEO of Aptuit said: "This partnership is an example of the developing new model of outsourced R&D collaborations. Verona staff are recognised industry-wide for their drug development expertise and will be an excellent addition to the Aptuit team."

In February 2010, GSK announced plans to cease discovery research in selected neuroscience areas, including depression and pain, to focus on neurodegenerative and neuroinflammatory diseases like Alzheimer's disease, multiple sclerosis and Parkinson's disease. These plans have a direct impact on the Italian R&D facility.

Aptuit specialises in providing contract development and manufacturing services to the pharmaceutical and biotech sectors. This latest acquisition will bring their global portfolio total to 19 locations.

1st July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics